国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
3期
317-319
,共3页
支气管扩张症%泛福舒胶囊(细菌溶解产物胶囊)%血气分析%免疫球蛋白
支氣管擴張癥%汎福舒膠囊(細菌溶解產物膠囊)%血氣分析%免疫毬蛋白
지기관확장증%범복서효낭(세균용해산물효낭)%혈기분석%면역구단백
Bronchiectasis%Broncho-Vaxom%Blood gas analysis%Immune globulin
目的 探讨泛福舒胶囊(细菌溶解产物胶囊)对中重度支气管扩张症患者的临床疗效.方法 将127例中重度支气管扩张症患者随机分为治疗组和对照组;对照组在伴发感染时予抗感染、平喘等治疗,治疗组在此基础上加用泛福舒胶囊(细菌溶解产物胶囊),每日晨空腹口服7 mg,连服10 d,停20 d,再连服10 d,停20 d,再连续10 d.连续使用3个月为1个疗程;连用3个疗程,两组均观察9个月,评价治疗前后血气分析PaO2(mmHg)、SaO2(%),血清IgG、IgA水平变化,呼吸道再发感染率(%)、平均住院日数(天)以及细菌刷检培养阳性率(≥103cfu/ml)的变化.结果 两组治疗前PaO2(mmHg)、SaO2(%)对比差异无显著性(P＞0.01),治疗后治疗组PaO2(mmHg)、SaO2(%)明显好于对照组(P＜0.01);两组治疗前血清IgG、IgA对比差异无显著性(P＞0.01),治疗后治疗组血清水平IgA较对照组有明显提高(P＜0.01),而血清中IgG两组无明显变化,均无统计学意义;治疗后呼吸道再发感染率(%),治疗组再发感染的机率明显少于对照组(P＜0.05);治疗后平均住院日数(天)治疗组明显少于对照组(P＜0.05);治疗后纤维支气管镜刷检检查,细菌刷检培养阳性率(≥103cfu/ml),治疗组的阳性率明显低于对照组(P＜0.05).结论 泛福舒胶囊(细菌溶解产物胶囊)能调节机体的免疫功能,提高呼吸道的抵抗力,有效改善中重度支气管扩张症患者的预后.
目的 探討汎福舒膠囊(細菌溶解產物膠囊)對中重度支氣管擴張癥患者的臨床療效.方法 將127例中重度支氣管擴張癥患者隨機分為治療組和對照組;對照組在伴髮感染時予抗感染、平喘等治療,治療組在此基礎上加用汎福舒膠囊(細菌溶解產物膠囊),每日晨空腹口服7 mg,連服10 d,停20 d,再連服10 d,停20 d,再連續10 d.連續使用3箇月為1箇療程;連用3箇療程,兩組均觀察9箇月,評價治療前後血氣分析PaO2(mmHg)、SaO2(%),血清IgG、IgA水平變化,呼吸道再髮感染率(%)、平均住院日數(天)以及細菌刷檢培養暘性率(≥103cfu/ml)的變化.結果 兩組治療前PaO2(mmHg)、SaO2(%)對比差異無顯著性(P＞0.01),治療後治療組PaO2(mmHg)、SaO2(%)明顯好于對照組(P＜0.01);兩組治療前血清IgG、IgA對比差異無顯著性(P＞0.01),治療後治療組血清水平IgA較對照組有明顯提高(P＜0.01),而血清中IgG兩組無明顯變化,均無統計學意義;治療後呼吸道再髮感染率(%),治療組再髮感染的機率明顯少于對照組(P＜0.05);治療後平均住院日數(天)治療組明顯少于對照組(P＜0.05);治療後纖維支氣管鏡刷檢檢查,細菌刷檢培養暘性率(≥103cfu/ml),治療組的暘性率明顯低于對照組(P＜0.05).結論 汎福舒膠囊(細菌溶解產物膠囊)能調節機體的免疫功能,提高呼吸道的牴抗力,有效改善中重度支氣管擴張癥患者的預後.
목적 탐토범복서효낭(세균용해산물효낭)대중중도지기관확장증환자적림상료효.방법 장127례중중도지기관확장증환자수궤분위치료조화대조조;대조조재반발감염시여항감염、평천등치료,치료조재차기출상가용범복서효낭(세균용해산물효낭),매일신공복구복7 mg,련복10 d,정20 d,재련복10 d,정20 d,재련속10 d.련속사용3개월위1개료정;련용3개료정,량조균관찰9개월,평개치료전후혈기분석PaO2(mmHg)、SaO2(%),혈청IgG、IgA수평변화,호흡도재발감염솔(%)、평균주원일수(천)이급세균쇄검배양양성솔(≥103cfu/ml)적변화.결과 량조치료전PaO2(mmHg)、SaO2(%)대비차이무현저성(P＞0.01),치료후치료조PaO2(mmHg)、SaO2(%)명현호우대조조(P＜0.01);량조치료전혈청IgG、IgA대비차이무현저성(P＞0.01),치료후치료조혈청수평IgA교대조조유명현제고(P＜0.01),이혈청중IgG량조무명현변화,균무통계학의의;치료후호흡도재발감염솔(%),치료조재발감염적궤솔명현소우대조조(P＜0.05);치료후평균주원일수(천)치료조명현소우대조조(P＜0.05);치료후섬유지기관경쇄검검사,세균쇄검배양양성솔(≥103cfu/ml),치료조적양성솔명현저우대조조(P＜0.05).결론 범복서효낭(세균용해산물효낭)능조절궤체적면역공능,제고호흡도적저항력,유효개선중중도지기관확장증환자적예후.
Objective To explor the curative effect of Broncho-Vaxom in patiens of severe and middle bronchiectasis.Methods Total 127 patiens were randomized to two groups, treatment group were receive treatment using Broncho-Vaxom, antibiotic and antasthmatic.Contrl group receive treatment only using antibiotic and antasthmatic .Results The difference of PaO2 ( mmHg ) and SaO2 ( % ) level before treatment was not significant between two groups( P＞0.01 ). The level of PaO2( mmHg ) and SaO2( % ) of treatment group obviously risen up compared to control group ( P＜ 0.01). There were not significant deviation of IgG and IgA level in blood serum before treatment between two groups( P＞0.01 ). The level of IgG and IgA of treatment group obviously risen up compared to control group ( P＜ 0.01 ). The case and probability of palindromia respiratory infection the same as hospital day were obviously lower compared to control group( P＜0.05 ). The positive rate of bacterial culture by BFS of treatment group was lower significantly compared to control group ( P＜ 0.05 ). Conclusion Broneho-Vaxom could regulate immunologic function of body and enhance defence of airway, it can effectively improve the prognosis of severe and middle bronchiectasis patients.
